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AbstrACt
Introduction Hip and knee arthroplasties have 
revolutionised the management of degenerative joint 
diseases and, due to an ageing population, are becoming 
increasingly common. Follow-up of joint prostheses is 
to identify problems in symptomatic or asymptomatic 
patients due to infection, osteolysis, bone loss or potential 
periprosthetic fracture, enabling timely intervention to 
prevent catastrophic failure at a later date. Early revision is 
usually more straight-forward surgically and less traumatic 
for the patient. However, routine long-term follow-up is 
costly and requires considerable clinical time. Therefore, 
some centres in the UK have curtailed this aspect of 
primary hip and knee arthroplasty services, doing so 
without an evidence base that such disinvestment is 
clinically or cost-effective.
Methods Given the timeline from joint replacement to 
revision, conducting a randomised controlled trial (RCT) 
to determine potential consequences of disinvestment 
in hip and knee arthroplasty follow-up is not feasible. 
Furthermore, the low revision rates of modern prostheses, 
less than 10% at 10 years, would necessitate thousands 
of patients to adequately power such a study. The huge 
variation in follow-up practice across the UK also limits 
the generalisability of an RCT. This study will therefore use 
a mixed-methods approach to examine the requirements 
for arthroplasty follow-up and produce evidence-based 
and consensus-based recommendations as to how, 
when and on whom follow-up should be conducted. Four 
interconnected work packages will be completed: (1) a 
systematic literature review; (2a) analysis of routinely 
collected National Health Service data from five national 
data sets to understand when and which patients present 
for revision surgery; (2b) prospective data regarding 
how patients currently present for revision surgery; (3) 
economic modelling to simulate long-term costs and 
quality-adjusted life years associated with different 
follow-up care models and (4) a Delphi-consensus 
process, involving all stakeholders, to develop a policy 
document which includes a stratification algorithm to 
determine appropriate follow-up care for an individual 
patient.
Ethics and Dissemination Favourable ethical opinion 
has been obtained for WP2a (RO-HES) (220520) and WP2B 
(220316) from the National Research Ethics Committee. 
Following advice from the Confidentiality Advisory Group 
(17/CAG/0122), data controllers for the data sets used in 
WP2a (RO-HES) – NHS Digital and The Phoenix Partnership 
– confirmed that Section 251 support was not required 
as no identifiable data was flowing into or out of these 
parties. Application for approval of WP2a (RO-HES) from 
the Independent Group Advising on the Release of Data 
(IGARD) at NHS Digital is in progress (DARS-NIC-147997). 
Section 251 support (17/CAG/0030) and NHS Digital 
approval (DARS-NIC-172121-G0Z1H-v0.11) have been 
strengths and limitations of this study
 ► Our mixed-methods approach allows us to address 
a question that would not be feasible to answer with 
a randomised controlled trial.
 ► Our study will capture data from a mixture of teach-
ing hospitals, district general hospitals and hospitals 
with a special interest in joint replacement and with 
a geographical spread, increasing the generalisabil-
ity of our results.
 ► Our economic model will be populated with rou-
tinely collected National Health Service (NHS) data 
of patients attending primary and hospital care in 
the UK, ensuring that our analysis is based on actual 
patient use of services, outcomes such as health-re-
lated quality of life and costs to the NHS.
 ► While our analysis is based on data sources that 
reflect clinical practice in England only, we believe 
key cost-effectiveness findings are likely to be infor-
mative for decision-making in the whole of the UK.
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obtained for WP2a (NJR-HES-PROMS). ISAC (11_050MnA2R2) approval 
has been obtained for WP2a (CPRD-HES).
IntroDuCtIon
Arguably, total hip arthroplasty (THA) and total knee 
arthroplasty (TKA) are the most successful surgical 
interventions performed in modern times. Due to an 
ageing population, and an obesity epidemic, hip and 
knee replacement procedures increase annually, rising 
from less than 20 000/year in the UK in 1978 to around 
200 000/year in 2017.1 The current follow-up require-
ments are estimated at 500 000–1 000 000 annual outpa-
tient attendances. With limitless resources, every patient 
undergoing a joint arthroplasty would incur routine life-
time follow-up. The rationale for follow-up is to ensure 
timely detection of complications or arthroplasty failure, 
such as aseptic loosening, osteolysis and potential peri-
prosthetic fracture. The cost of revision for aseptic loos-
ening is 35% lower than that for periprosthetic fractures 
and has a lower incidence of complications which impact 
recovery.2 However, while routine long-term follow-up of 
joint prostheses may support timely revision for patients 
with asymptomatic complications, improving long-term 
health outcomes, it is also costly both clinically and 
financially.
Orthopaedic services are already one of the poorest 
performers across the National Health Service (NHS) 
by failing to meet waiting list targets, with an estimated 
8000 orthopaedic NHS breaches each month.3 With a 
rapidly ageing population and medical advances that 
mean less stringent criteria for surgery eligibility,4 there 
is no sign that demand will recede in coming years and 
orthopaedic services will soon reach breaking point. To 
reduce the burden on orthopaedic services, evidence-
based consensus guidelines are required to establish how, 
when and on whom follow-up should be conducted.
British Hip Society (BHS) and British Orthopaedic 
Association (BOA) guidelines recommend outpatient 
follow-up at 1 and 7 years, and every 3 years thereafter 
for Orthopaedic Data Evaluation Panel 10A (ODEP-10A) 
implants, with more frequent follow-up for novel 
implants.5 However, recent work revealed considerable 
diversity across the UK in arthroplasty follow-up path-
ways, in timing, how follow-up is conducted and which 
health professionals are involved.6While some centres 
followed-up patients beyond 10 years, others did not 
have an established follow-up policy and in some centres 
follow-up services have been curtailed or stopped entirely 
after an early postoperative check.6 Notably, we do not 
know whether long-term follow-up is cost-effective or 
whether disinvestment is safe for patients.
This project aims to determine the consequences of 
disinvestment in hip and knee arthroplasty follow-up. 
Given the timeline from joint replacement to revision, 
with a 7% revision rate for THA and 4% revision rate for 
TKA at 14 years, conducting a randomised controlled 
trial to address this question is not feasible. Moreover, the 
huge variation in follow-up practice across the UK limits 
the generalisability of the results of an RCT. We will there-
fore use a mixed-methods approach to comprehensively 
evaluate the requirements for arthroplasty follow-up 
and will use this evidence to inform the development of 
consensus-based recommendations and a policy docu-
ment which includes a stratification algorithm to deter-
mine appropriate follow-up for individual patients. 
Disinvestment is a complex and often contentious issue. 
We plan to make use of published recommendations7 to 
ensure that the results of this work are understood and 
considered as a genuine attempt to use the best evidence 
available to ensure that the NHS gets value for money and 
that patients remain safe.
MEthoDs AnD AnAlysIs
study objectives
A. Identify who needs follow-up and when this should 
occur for primary THA, TKA and unicompartmental 
knee arthroplasty (UKA) surgery by making use of 
routinely collected NHS data.
B. Understand the patient journey (in primary and sec-
ondary care) to revision surgery by recruiting patients 
admitted for elective and emergency hip and knee re-
vision surgery.
C. Establish how and when patients are identified for 
revision, why some patients are missed from regular 
follow-up and present acutely with fracture around the 
implant (periprosthetic fracture), by using prospec-
tive and retrospective data.
D. Identify the most appropriate and cost-effective fol-
low-up pathway to minimise potential harm to patients 
by undertaking cost-effectiveness modelling.
E. Provide evidence-based and consensus-based recom-
mendations on how follow-up of primary THA and 
TKA should be conducted.
Design
This is a mixed-methods study using a variety of data 
sources consisting of four interconnected work packages 
(WP): (1) a systematic literature review; (2a) analysis of 
routinely-collected NHS data to understand when and 
which patient present for revision surgery; (2b) prospec-
tive data regarding how patients currently present for 
revision surgery collected on around 455 patients prior 
to elective or emergency revision surgery; (3) economic 
modelling to simulate long-term costs and quality adjusted 
life years associated with different follow-up models; (4) a 
Delphi-consensus process, incorporating all previous WPs 
and involving all stakeholders, to develop a policy docu-
ment which includes a stratification algorithm to deter-
mine appropriate follow-up for an individual patient.
WP1: systematic review
The aim of the review is to evaluate different models of 
routine long-term follow-up care after TKA/THA/UKA. 
This systematic review will establish a robust evidence base 
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for the cost-effectiveness modelling (WP3) and consensus 
guideline development (WP4).
Registration
This systematic review will be undertaken following 
Cochrane Collaboration methods8 and reported in accor-
dance with Preferred Reporting Items for Systematic 
Review and Meta-analyses guidelines.9 It has been prospec-
tively registered with PROSPERO (CRD42017053017).
Searches
A comprehensive literature search will be undertaken with 
the aim of retrieving all relevant literature, published or 
unpublished, which evaluated the effectiveness of long-
term follow-up after primary TKA/THA/UKA. A range of 
information sources will be searched: BIOSIS, CINAHL, 
ClinicalTrials. gov, The Cochrane Library, Embase, Health 
Management Information Consortium, IDEAS (RePEC), 
Ovid Medline(R), ProQuest Dissertations and Theses, 
PsycINFO, PubMed and Web of Science. Reference lists of 
included studies will be reviewed for potentially relevant 
articles. A sample search strategy is detailed in the online 
supplementary appendix A. No date or language restric-
tions will be applied.
Criteria for selection of studies
All study designs will be included which (1) consider 
the clinical and/or cost effectiveness of routine long-
term (>5 years) follow-up care after primary THA, TKA 
or UKA; (2) describe patient safety issues associated with 
routine follow-up or (3) consider the acceptability of new 
care pathways from the perspective of the patient and/or 
practitioner. Studies will be excluded if they do not report 
specific patient-related outcome measures or appropriate 
health utility measures.
Selection of studies
Titles/abstracts of identified studies will be screened for 
eligibility by one experienced reviewer with a random 
selection (25%) independently screened by a second. 
Potential studies will be retrieved in full text and reviewed 
against the inclusion/exclusion criteria independently 
by the same two reviewers, with a third reviewer used to 
settle any disputes.
Data extraction
Data will be extracted by a single reviewer using a stan-
dardised proforma capturing (1) purpose and design; (2) 
methodological characteristics; (3) information relating 
to quality assessment and (4) outcome data relating to 
the clinical and cost-effectiveness of routine long-term 
follow-up care.
Quality assessment
The Cochrane Risk of Bias assessment tool will be used 
for experimental studies,10 and the Newcastle-Ottawa 
scales for cohort and case–control studies.11 Qualita-
tive literature will be assessed using critical interpretive 
synthesis.12 Economic evaluations will be assessed using 
the Drummond checklist.13 Studies will be evaluated 
independently by two reviewers, with a third to settle any 
disputes. Studies at high risk of bias will not be excluded 
and conclusions will incorporate observed biases.
Evidence synthesis
The design, methodological characteristics, study quality 
and main findings will be summarised in narrative and 
tabular form. We anticipate substantial heterogeneity 
among included studies precluding the use of meta-anal-
ysis techniques.
WP2a: Analysis of routinely collected nhs data
This WP will use routinely collected NHS data to deter-
mine when revision happens and to identify patients most 
likely to require revision in order to target when and on 
whom follow-up should occur.
Data sources
Data from five national datasets will be used: (1) Clinical 
Practice Research Database (CPRD),14 (2) ResearchOne 
(RO),15 (3) Hospital Episode Statistics (HES),16 (4) 
National Joint Registry (NJR)17 and (5) patient reported 
outcome measures (PROMs).18
Three linked data sets will be constructed for analysisː 
(a) CPRD–HES–PROMS, which preexists at the University 
of Oxford, (b) RO–HES will be constructed and analysed 
at the University of Leeds. Linkage will be undertaken 
by NHS Digital on the basis of pseudonyms generated 
from NHS numbers by the data providers. (c) NJR–HES–
PROMS will be constructed and analysed at the University 
of Oxford. Linkages will be undertaken by NHS Digital, 
using an agreed set of common patient identifiers, 
including NHS number. Data sets (a) and (b) provide a 
primary care view (eg, prior diagnoses, prescribing) and 
include different, representative patient populations for 
cross-validation; data set (c) provides a secondary care 
view (eg, surgeon, procedure details).
Data analysis
The primary outcome of the analysis will be mid-late 
term revision (>5 years post-primary surgery), defined as 
the removal, exchange or addition of any of the compo-
nents of arthroplasty. Exposures will include secondary 
care predictors, including patient level characteristics 
recorded in NJR and HES (eg, age, body mass index 
(BMI)), surgical and operative factors and symptoms of 
pain, function and health-related quality of life preop-
eratively and 6 months post-surgery from PROMS, and 
primary care predictors, including patient demographics, 
comorbidities and use of drugs which can affect fracture 
risk. Survival analysis will be used to model time to revi-
sion.19 20 The smoothed Nelson-Aalen cumulative hazard 
rate will be examined to identify any peak in the mid-long 
term risk of revision. Cox proportional hazards regression 
modelling will be used to identify preoperative, perioper-
ative and postoperative predictors of mid-late term revi-
sion, for example, age, BMI, comorbidities, implant type, 
surgeon skill and postoperative problems. Competing risk 
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regression will be used, since mortality can be regarded 
as a competing risk for revision surgery.21 22 To account 
for clustering within the data (such as patients nested 
within hospitals), a multilevel survival model will be fitted 
by extending the survival regression model to include a 
frailty term with a Gaussian distribution.23
WP2b part 1: multicentre observational prospective cohort
Prospective data collection from patients undergoing 
revision surgery.
Objectives:
 ► Identify all recent (previous 12 months) medical 
appointments and advice sessions related to the index 
joint in primary and secondary care.
 ► Establish if the patient has been seen by orthopaedic 
health professionals from 12 months after primary 
surgery until this hospital admission, that is, was the 
revision directed by routine follow-up.
Design
A multicentre, observational, single visit, prospective 
cohort study of patients admitted for revision hip or knee 
surgery.
Population
Patients presenting for elective and emergency revision 
surgery of a primary THA, TKA or UKA and who are 
able and willing to provide written informed consent 
will be included in the study. Patients will be excluded 
if they have had previous revision surgery; metal-on-
metal primary joint replacement or hip hemiarthroplasty. 
Participants will be recruited from a sample of hospitals 
selected to provide geographical spread and representa-
tion of teaching hospitals, district general hospitals and 
hospitals with a special interest in joint replacement
Data collection
A participant case report form (CRF) will capture details 
of follow-up after primary surgery and pathway to current 
revision surgery, including symptom state. An investi-
gator CRF will extract data from medical notes including 
demographics (age, gender, diagnosis leading to primary 
surgery, medical history), general practitioner and 
hospital appointments, details of primary and revision 
surgery (including implant type, complications, length of 
stay). The participant CRF will be piloted with the Leeds 
Biomedical Research Centre Patient and Public Involve-
ment (PPI) group and the investigator CRF with two 
research nurses to ascertain the comprehension, usability 
and completeness of data subsequently extracted.
Sample size
We will use stratified sampling to recruit centres of varying 
size and anticipate that the average number of patients 
per centre will be 45 (based on NJR records and infor-
mation from prospective centres). We initially anticipated 
the recruitment of 25 centres. With a recruitment rate 
of 60%, this gave 27 recruited patients from 25 centres 
(n=675). We do not know the intraclass correlation coef-
ficient (ICC) for our primary outcome (‘Was the revision 
a result of routine follow-up?’), but we anticipate it to be 
in the region of 0.01–0.05. To be conservative, we use 
ICC=0.05. This gives a design factor of 2.3 and hence an 
effective sample size of 293 after accounting for clustering 
within centre. The enrolment of 35 centres reduced the 
design factor to 1.6 and the total sample size required to 
455. From previous research,6 we estimate that the rate of 
our primary outcome is 20% so that the effective number 
of events will be 58. Hence, we will have sufficient power 
for our logistic regression to robustly estimate the coeffi-
cients of up to five potential risk factors derived from our 
brief patient survey.24
Analysis
The primary outcome will be ‘revision identified through 
routine follow-up’, and this will be modelled through a 
multilevel logistic regression model, with a centre-level 
random intercept of particular interest. The size of the 
centre-level effect will be assessed as the proportion of 
variance explained and will also be assessed through a 
likelihood ratio test. Up to five factors from the patient 
questionnaire will be explored as fixed effects at the 
patient level. This will adjust for case mix. Factors that 
are found to be both clinically and statistically significant 
could potentially contribute to a stratified approach to 
follow-up.
WP2b part 2: qualitative study
Building on previous work highlighting the changes in 
follow-up practice,6 this WP aims to explore the rationale 
and motivating factors behind these changes, the facili-
tators and the evidence considered when implementing 
new pathways, including no follow-up.
Sampling
A sample of n=20–30 orthopaedic practitioners and/or 
unit managers will be recruited. Purposive sampling via 
sampling matrix will recruit participants with different 
experiences of a range of follow-up pathways while 
reflecting NHS trust type, geographical area (urban, 
rural); socioeconomic area (low/high socioeconomic 
status) and diverse ethnicity. Some selection criteria are 
likely to be nested (eg, hospital type, geographical area) 
and care will be taken to ensure that all viewpoints are 
represented.
Data collection
Semistructured, telephone interviews following a topic 
guide refined from the literature review and expert 
opinion (clinician coapplicants/advisors and PPI 
members). The researcher will probe pertinent initial 
responses and expand on issues raised. Interviews will be 
recorded and transcribed verbatim.
Data analysis
The guiding approach will be framework analysis.25 Data 
analysis will comprise five stages: (1) data familiarisation; 
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(2) identifying the thematic framework; (3) indexing; 
(4) charting and (5) mapping and interpreting. The 
process of familiarisation enables the researcher to iden-
tify emerging themes or issues in the data. Little is known 
about why NHS trusts have chosen to either withdraw 
follow-up care or change the way it is delivered. The 
evidence generated from the literature review and input 
from our clinical coapplicants will be used to help iden-
tify and refine the thematic framework. Themes are flex-
ible and can be modified in the light of new data, and a 
process of constant comparison will be undertaken across 
themes and cases.
WP3
As previous work conducted by members of our team 
has identified considerable heterogeneity in current 
follow-up pathways,6 our cost-effectiveness analysis will 
compare the relative costs and quality-adjusted life 
years associated with having follow-up compared with 
not having follow-up. A third hypothetical scenario of a 
virtual follow-up will be considered.
Comparators
Both the findings from our systematic review and the 
prospective cohort will inform the criteria to be used to 
identify patients as having or not having follow-up. The 
7-year reference point for a follow-up currently suggested 
by BHS and BOA guidelines is likely to be incorporated. 
Patients having an orthopaedic outpatient appoint-
ment around the reference point(s) following a primary 
arthroplasty will be used to group patients in the CPRD–
HES–PROMS data set into the follow-up and no follow-up 
groups. Joint-specific revision procedures will be identi-
fied by OPCS-4 codes as reported in the Admitted Patient 
Care data set within HES, with corresponding linked 
records to primary care and PROMS.
Model structure
To identify the most appropriate modelling approach 
for the question and data at hand, we will conduct a 
series of preliminary analysis to determine if a cohort-
level or patient-level decision analytic model should be 
employed. Previous models examining the long-term 
cost-effectiveness of hip and knee replacements have 
used cohort Markov models.26 27 Analyses will include 
associations between patients’ characteristics and revision 
rates, health utilities and costs and whether the risk for 
revision depends on the time patients stay unrevised after 
their primary. Regardless of the chosen model type, the 
key health state or event will be revision arthroplasty, with 
death and complications also considered. The model will 
be designed to cover patients’ lifetime and analysed from 
an NHS and Personal Social Services perspective, with 
discounting of costs and outcomes as per current guide 
to the methods of technology appraisal.28
Model inputs
WP2 data sets will be used to quantify primary and 
hospital healthcare resource use for comparator groups 
of follow-up care models through estimation of NHS 
costs and health-related quality of life (HRQoL). The 
economic model will simulate long-term costs and quality 
adjusted life years (QALYs) associated with each care 
model. Primary care costs will include consultations, 
and hospital costs will be derived by grouping hospital 
episodes into Health Resource Groups, a set of casemix 
groupings utilising similar levels of healthcare resources. 
Panel data regression analysis29–31 will be used to estimate 
hospital costs conditional on patient characteristics and 
comorbidities. QALYs and transition probabilities will be 
derived from the linked data sets and published literature 
as needed. The hypothetical costs of virtual follow-up will 
be based on similar virtual clinic alternatives previously 
studied and NHS X-ray-associated costs.
Analysis
Cost-effectiveness analyses will be performed separately 
for relevant patient subgroups based on gender, age and 
other potential covariates for which data may be available. 
As with all economic models, a number of assumptions 
will be made, and their plausibility and potential impact 
discussed, relating to model structure and input param-
eters for transition probabilities, health utilities and 
costs, including the cost of periprosthetic fractures if no 
reference is found for these in the literature. Sensitivity 
analyses will be conducted to explore the uncertainty asso-
ciated with key assumptions and model parameters and 
the implications of using different estimates discussed.
WP4: Delphi-consensus process
This WP will use the collective evidence from WP1–3 to 
inform a consensus process to determine appropriate 
follow-up care pathways for hip and knee arthroplasty.
Evidence gathered from WP1–3 will feed into a 
consensus panel workshop. We intend to use methods 
employed by the National Institute for Health and 
Care Excellence (NICE) in both the technology assess-
ment committees and Guideline Development Groups. 
The expert stakeholders invited to attend will have a 
special interest in patient follow-up after hip or knee 
replacement surgery. Participants will include patients, 
orthopaedic surgeons, arthroplasty practitioners, NHS 
managers and commissioners, manufacturers and repre-
sentatives of the major orthopaedic bodies (including 
BOA, BHS and BASK). The purpose of this exercise is to 
consider the evidence and obtain agreement for future 
care pathways, supported by the evidence of their effec-
tiveness and cost-effectiveness, to be recommended and 
adopted across the NHS. Following the NICE consensus 
model all participants will receive summaries of the main 
research findings in advance. There will be presentations 
from the work-stream leaders to outline the evidence for 
consideration.
Robert et al7 demonstrate that decommissioning is often 
about more than the ‘evidence’ and that withdrawal of 
previously available services is often seen as being driven 
by the wrong kind of evidence, based on cost data and 
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political priorities and not on what patients and service 
users value.7 It is a complex issue, perhaps as contentious 
as NICE decisions when they do not fund an effective 
intervention because it exceeds the threshold. However, 
NICE investment decisions are made with the explicit 
understanding that, with no increase in the budget, there 
must be some displacement of other healthcare technol-
ogies.32 We plan to make use of the recommendations for 
engagement and the use of evidence outlined in Robert 
et al to ensure the results of this work are understood and 
considered as a genuine attempt to use the best evidence 
available to ensure that the NHS gets value for money and 
that patients remain safe.
Patient and public involvement
Members of the NIHR Leeds BRC, Oxford and Bristol PPI 
groups are involved in UK SAFE. The PPI co-applicant is a 
member of the study steering committee and contributes 
across all WPs. Two independent PPI advisors sit on the 
Independent Advisory Group. Specific areas where lay 
involvement will be pivotal include the interpretation of 
results of the systematic review, the expert panel discus-
sion and consensus process, study oversight (steering 
group), preparation of patient material and study results 
and contribution to reports and newsletters for patients 
and NHS staff.
EthICs AnD DIssEMInAtIon
All studies will be conducted in accordance with the 
principles of Good Clinical Practice, and the UK Policy 
Framework for Health and Social Care Research, 2018. 
Favourable ethical opinion has been obtained for 
WP2a (RO-HES) (220520) and WP2B (220316) from 
the National Research Ethics Committee. Following 
advice from the Confidentiality Advisory Group (17/
CAG/0122), data controllers for the data sets used in 
WP2a (RO–HES)—NHS Digital and The Phoenix Part-
nership—confirmed that Section 251 support was not 
required as no identifiable data was flowing into or 
out of these parties. Application for approval of WP2a 
(RO–HES) from the Independent Group Advising on 
the Release of Data (IGARD) at NHS Digital is in prog-
ress (DARS-NIC-147997). Section 251 support (17/
CAG/0030) and NHS Digital approval (DARS-NIC-
172121-G0Z1H-v0.11) have been obtained for WP2a 
(NJR-HES-PROMS). ISAC (11_050MnA2R2) approval 
has been obtained for WP2a (CPRD–HES).
At the end of the project, outputs will be disseminated 
nationally in the form of an executive summary state-
ment of the agreed pathway/s through appropriate NHS 
Networks, NICE, the NHS England Elective Orthopaedics 
Sub-committee, the NHS Institute for Innovation and 
Improvement and professional societies, including BHS, 
BOA, BASK, Arthroplasty Care Practitioners Association 
and the NJR. Dissemination will be key to developing a 
culture of ‘finding the best way of doing something and 
doing it everywhere’ to significantly reduce wastage of 
clinical resources and optimise NHS spend. We will put 
forward the consensus statement to each society’s AGM 
for adoption as a resolution. Internationally, dissemina-
tion platforms are in place through the International 
Society of Arthroplasty Registers (ISAR) and the Euro-
pean Federation of National Associations of Orthopae-
dics and Traumatology. A lay summary of the project will 
be produced for study participants. Findings will also 
be presented at relevant orthopaedic and methodolog-
ical conferences, such as the BOA and the Exploiting 
Existing Data for Health Research conference. The chief 
investigator and co-applicants will be named as authors 
on main publications, and an appropriate first author 
agreed through discussion. Other key individuals will 
be included as authors or contributors as appropriate, 
at the discretion of the Senior Management Group. Any 
disputes relating to authorship will be resolved by the 
Steering Committee.
The Chair and Independent members of the Steering 
Committee will be acknowledged, but will not qualify 
for full authorship, in order to maintain their indepen-
dence. Individual collaborators must not publish data 
concerning their participants’ which are directly relevant 
to the questions posed in the study until the main results 
of the study have been published.
ConClusIon
This research will deliver the first research-supported, 
best-for-patient, joint-specific, cost-effective recommen-
dations for follow-up pathways, providing a gold standard 
for clinical excellence and follow-up advice for patients, 
surgeons, purchasers and the NHS as a whole. Value is 
not limited to the UK, but has substantial global impact 
potential.
The impact of this work will be to reduce the burden 
on patients and the NHS in terms of outpatient visits and 
clinical tests that do not add benefit, while optimising 
detection of potential problems. From an NHS perspec-
tive, this work will provide managers with economic and 
clinical information on arthroplasty follow-up to inform 
service planning and delivery, and the role of arthro-
plasty practitioners in this service, with the potential to 
reduce geographical disparity through NHS trusts model-
ling their service provision on a national evidence-based 
guideline; provide orthopaedic surgeons with guidance 
on follow-up, including patient and economic consider-
ations of factors involved; produce arthroplasty follow-up 
guidelines for adoption by the relevant specialist soci-
eties and information for their members. From a patient 
perspective, this work will help to inform patients about 
follow-up practice, empower them to make choices about 
future healthcare relating to their joint arthroplasty 
and provide reassurance that their follow-up pathway is 
appropriate
The outputs of this project, in terms of evidence-based 
support for timing of follow-up and identification of the 
most cost-effective follow-up model, fit directly within the 
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NHS framework for improving outcomes from elective 
procedures. Rationalising current diversity of follow-up 
practices should enable substantial savings for the NHS. 
We envisage outputs to be readily applicable to the wider 
NHS, not only hip and knee but also other joint replace-
ments. With the committed support of key national and 
international organisations already in place, we anticipate 
that these guidelines will be positively received and that 
implementation will be widespread.
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